StreetInsider.com News Articles

Raymond James: 'The topline numbers presented by Black Diamond today indicate that the company has a viable asset in our view'

Fri, 22 May 2026 09:38:44 -0400

Raymond James analyst Sean McCutcheon reiterated an Outperform rating and $11.00 price target on Black Diamond Therapeutics (NASDAQ: BDTX).

The analyst comments "Thursday, after market close, ASCO 2026 regular abstracts were released, and in conjunction Black Diamond reported the topline result for the longer-term follow-up from their Phase 2 study testing silevertinib in 1L non-classical EGFR mutant (EGFR NCM) NSCLC. Management also hosted a call to discuss the disclosure. Recall we previously saw the initial response rate data during December 2025 (our commentary), which we think hit the mark in a highly heterogenous NCM population, though left some uncertainty on tolerability/ability

Raymond James: 'The topline numbers presented by Black Diamond today indicate that the company has a viable asset in our view'

Fri, 22 May 2026 09:38:44 -0400

Raymond James analyst Sean McCutcheon reiterated an Outperform rating and $11.00 price target on Black Diamond Therapeutics (NASDAQ: BDTX).

Stifel Defending Black Diamond Therapeutics (BDTX): 'we believe investors are underappreciating the breadth of mutation silevertinib is showing'

Fri, 22 May 2026 09:37:35 -0400

Stifel analyst Laura Prendergast reiterated a Buy rating and $8.00 price target on Black Diamond Therapeutics (NASDAQ: BDTX).

The analyst comments "We view the preliminary median PFS of 15.2 months as highly encouraging and perhaps practice changing - the DoR had not yet been reached. 44% of patients are progression free/still on drug with median follow up ~9.8 months, suggesting PFS could increase with longer follow up. What stands out to us the most is: • The breadth of mutations seen in patients who are progression free for ≥1 year (10 unique mutations across 8 patients). • The lack of any

Stifel Defending Black Diamond Therapeutics (BDTX): 'we believe investors are underappreciating the breadth of mutation silevertinib is showing'

Fri, 22 May 2026 09:37:35 -0400

Stifel analyst Laura Prendergast reiterated a Buy rating and $8.00 price target on Black Diamond Therapeutics (NASDAQ: BDTX).

TD Cowen on Black Diamond Therapeutics (BDTX) Amid 18% Drop: 'is unclear if the FDA will require Ph3 run-in or additional Ph2 dosing work extending competitor's lead'

Fri, 22 May 2026 09:36:24 -0400

TD Cowen analyst Marc Frahm reiterated a Buy rating and {REMOVEPT} price target on Black Diamond Therapeutics (NASDAQ: BDTX).

The analyst comments "BDTX shared updated 1L data for 200mg silevertinib, including a preliminary mPFS of 15.2m, 60% ORR (86% CNS), and slightly increased dose-reduction of 84%. Mgmt plans to discuss Ph3 pivotal plans including a proposed 150mg dose with the FDA in H2. While 150mg dose selection appears wise, it is unclear if the FDA will require Ph3 run-in or additional Ph2 dosing work extending competitor's lead."

For an analyst ratings summary and ratings history on Black Diamond Therapeutics click here.

TD Cowen on Black Diamond Therapeutics (BDTX) Amid 18% Drop: 'is unclear if the FDA will require Ph3 run-in or additional Ph2 dosing work extending competitor's lead'

Fri, 22 May 2026 09:36:24 -0400

TD Cowen analyst Marc Frahm reiterated a Buy rating and {REMOVEPT} price target on Black Diamond Therapeutics (NASDAQ: BDTX).

For an analyst ratings summary and ratings history on Black Diamond Therapeutics click here.

Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference

Fri, 22 May 2026 08:00:00 -0400

CAMBRIDGE, Mass., May 22, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced that its Chief Executive Officer, Mark Velleca, M.D., Ph.D., will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 3, 2026, in New York, NY. In addition, the company will host one-on-one meetings with investors on the same day.

Presentation details are as follows:

4:55-5:25pm ET on Wednesday, June 3

The

Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference

Fri, 22 May 2026 08:00:00 -0400

Presentation details are as follows:

4:55-5:25pm ET on Wednesday, June 3

The

H.C. Wainwright Reiterates Buy Rating on Black Diamond Therapeutics (BDTX)

Fri, 22 May 2026 06:57:27 -0400

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $11.00 price target on Black Diamond Therapeutics (NASDAQ: BDTX).

The analyst commented: "Yesterday, Black Diamond presented updated Phase 2 results, including duration of response (DOR) and progression-free survival (PFS) results, for silevertinib (BDTX-1535) in 1L NSCLC patients harboring non-classical EGFR mutations. As seen in the company's presentation, silevertinib (n=43; 44% brain metastases; 74% Caucasian) achieved a 60% [26/43] confirmed objective response rate (cORR) and an 86% [6/7] intracranial cORR in NSCLC patients with non-classical EGFR mutations treated in the 1L setting (see Figure 1 overleaf). Responses were seen across 33 distinct

Form 8-K Black Diamond Therapeuti For: May 21

Thu, 21 May 2026 17:19:00 -0400

si-local-file:///var/storage/secattach/20260521/26536895.html

Form 8-K Black Diamond Therapeuti For: May 21

Thu, 21 May 2026 17:19:00 -0400

si-local-file:///var/storage/secattach/20260521/26536895.html

Black Diamond reports phase 2 lung cancer trial results for silevertinib

Thu, 21 May 2026 17:14:07 -0400

Black Diamond Therapeutics Inc. (NASDAQ: BDTX) announced results from a Phase 2 trial of silevertinib in treatment-naïve non-small cell lung cancer patients with epidermal growth factor receptor non-classical mutations.

The trial enrolled 43 patients who received 200 mg once daily of silevertinib. Results showed a preliminary median progression-free survival of 15.2 months, with median duration of response not yet reached. The objective response rate was 60% and disease control rate was 91%.

Among 19 patients with brain metastases, the central nervous system objective response rate was 86%. No patients developed new brain metastases during treatment.

The safety profile showed treatment-related adverse events greater

Black Diamond reports phase 2 lung cancer trial results for silevertinib

Thu, 21 May 2026 17:14:07 -0400

Among 19 patients with brain metastases, the central nervous system objective response rate was 86%. No patients developed new brain metastases during treatment.

The safety profile showed treatment-related adverse events greater

Black Diamond reports phase 2 lung cancer trial results for silevertinib

Thu, 21 May 2026 17:14:07 -0400

Among 19 patients with brain metastases, the central nervous system objective response rate was 86%. No patients developed new brain metastases during treatment.

The safety profile showed treatment-related adverse events greater

Black Diamond reports phase 2 lung cancer trial results for silevertinib

Thu, 21 May 2026 17:14:07 -0400

Among 19 patients with brain metastases, the central nervous system objective response rate was 86%. No patients developed new brain metastases during treatment.

The safety profile showed treatment-related adverse events greater

Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations